Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6...
Melanoma
IO Biotech, Inc. Announces $75 Million Private Placement Financing
Offering includes participation from both new and existing healthcare-dedicated investorsProceeds extend the company’s cash runway into the fourth quarter of...
Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv
LAWRENCEVILLE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral...
Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62Company expecting 2023...
IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023
LAWRENCEVILLE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated...
Advanced Health Intelligence to re-enter China with Exclusive License Deal with Changlin Network Technology Ltd
HighlightsAHI executes a binding exclusive, perpetual license with Shanghai-based Changlin Network Technology Ltd.Changlin is backed by founders with 50 years...
Marpe Technologies Receives FDA Breakthrough Device Designation for its Revolutionary Dermatology Screening System
CAESAREA, ISRAEL / ACCESSWIRE / July 31, 2023 / Marpe Technologies, a leading innovator in dermatology screening solutions, is thrilled...
IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
Quarterly Activities Update: Encouraging Growth for geneType Commercial Test Volume
Customer Cash Receipts (A$'000) Customer Cash Receipts (A$'000)MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”,...
Sensus Healthcare to Host Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 3, 2023
BOCA RATON, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology...
DermaSensor Presents Study Results on Melanoma Detection in a Medicare Population at American Dermoscopy Meeting
DermaSensor’s Device with FDA Breakthrough Designation Demonstrated 96.2% Sensitivity for Detecting Melanoma in Patients Aged 65 and OlderMIAMI--(BUSINESS WIRE)--DermaSensor Inc.,...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab
SHANGHAI, China, July 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC)...
Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Thursday, July 13th at 2:00 PM ETBERWYN, Pa., July 05, 2023 (GLOBE NEWSWIRE) -- Panavance...
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
YUSIMRY™ (adalimumab-aqvh) product image YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for...
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
PRESS RELEASE - REGULATED INFORMATION 30 June 2023, 7:00 CEST Disclosure of Outstanding Voting Securities Mechelen, Belgium, 30 June 2023...
Advanced Health Intelligence Ltd Announces Implementation of ADS Ratio Change
NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Advanced Health Intelligence Ltd (ASX/NASDAQ:AHI) (“Advanced Health Intelligence”, “AHI” or the “Company”)...
Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)
Data indicate that GP-2250 has anti-neoplastic effects in virus-negative MCC cells as evidenced by tumor cell viability, proliferation and migrationGP-2250...